Although the expression of programmed death ligands 1 and 2 (PD-L1 and PD-L2) on PC cells is highly variable, therapy with enzalutamide can upregulate PD-L1 expression in the tumor microenvironment; this can represent a mechanism of resistance by inducing immune evasion [75]. The gene discussed is CD274; the disease is neoplasm.